Hepatitis-C virus testing
AssigneeCommon Services Agency
InventorsPeter Simmonds, Shui-Wan Chan, Peng Lee Yap
Life of this patent
Estimating the term…
Abstract
New styles of hepatitis C virus (HCV), referred to as HCV-3 and HCV-4, have been identified and sequenced. Antigenic regions of HCV-2, HCV-3 and HCV-4 polypeptides have been identified. Immunoassays for HCV and antibodies thereto are described, which allow more complete screening of blood samples for HCV, and allow HCV genotyping.
Claims27
An isolated polynucleotide molecule having a sequence encoding a polypeptide selected from the group consisting of:
- (a) KPALVPDKEVLYQQYDEM (SEQ ID NO:1);
- (b) ECSQAAPYIEQAQVIAHQF (SEQ ID NO:2);
- and
- (c) a polypeptide of equivalent antigenicity, which polypeptide specifically binds to the same antibodies as are bound by the polypeptide of (a) or (b) above.
A peptide selected from the group consisting of:
- (a) KPALVPDKEVLYQQYDEM (SEQ ID NO:1),
- (b) ECSQAAPYIEQAQVIAHQF (SEQ ID NO:2), and
- (c) a polypeptide of equivalent antigenicity, which polypeptide specifically binds to the same antibodies as are bound by the polypeptide of (a) or (b) above.
An antigenic HCV-3 type-specific peptide comprising an NS4 epitope, said NS4 epitope having a sequence corresponding to amino acids 1691 to 1708 or to amino acids 1710 to 1728 of HCV-3 NS4 polypeptide, numbered according to a prototype HCV-1 amino acid sequence.
An antigenic HCV-3 nonameric oligopeptide selected from the group consisting of:
- (a) KPALVPDKE (sequence 13 of FIG. 11a;
- residues 1 to 9 in SEQ ID NO:
- 1);
- (b) PALVPDKEV (sequence 14 of FIG. 11a;
- residues 2 to 10 in SEQ ID NO:
- 1);
- (c) ALVPDKEVL (sequence 15 of FIG. 11a;
- residues 3 to 11 in SEQ ID NO:
- 1);
- (d) LVPDKEVLY (sequence 16 of FIG. 11a;
- residues 4 to 12 in SEQ ID NO:
- 1);
- (e) VPDKEVLYO (sequence 17 of FIG. 11a;
- residues 5 to 13 in SEQ ID NO:
- 1);
- (f) PDKEVLYOO (sequence 18 of FIG. 11a;
- residues 6 to 14 in SEQ ID NO:
- 1);
- (g) DKEVLYOOY (sequence 19 of FIG. 11a;
- residues 7 to 15 in SEQ ID NO:
- 1);
- (h) KEVLYOOYD (sequence 20 of FIG. 11a;
- residues 8 to 16 in SEQ ID NO:
- 1);
- (i) EVLYOOYDE (sequence 21 of FIG. 11a;
- residues 9 to 17 in SEQ ID NO:
- 1);
- (j) VLYOOYDEM (sequence 22 of FIG. 11a;
- residues 10 to 18 in SEQ ID NO:
- 1);
- (k) ECSOAAPYI (sequence 32 of FIG. 11a;
- residues 1 to 9 of SEQ ID NO:
- 2);
- (l) CSOAAPYIE (sequence 33 of FIG. 11a;
- residues 2 to 10 of SEQ ID NO:
- 2);
- (m) SOAAPYIEO (sequence 34 of FIG. 11a;
- residues 3 to 11 of SEQ ID NO:
- 2);
- (n) OAAPYIEOA (sequence 35 of FIG. 11a;
- residues 4 to 12 of SEQ ID NO:
- 2);
- (o) AAPYIEOAO (sequence 36 of FIG. 11a;
- residues 5 to 13 of SEQ ID NO:
- 2);
- (p) APYIEOAOV (sequence 37 of FIG. 11a;
- residues 6 to 14 of SEQ ID NO:
- 2);
- (q) APYIEOAOV (sequence 38 of FIG. 11a;
- residues 7 to 15 of SEQ ID NO:
- 2);
- (r) YIEOAOVIA (sequence 39 of FIG. 11a;
- residues 8 to 16 of SEQ ID NO:
- 2);
- (s) IEOAOVIAH (sequence 40 of FIG. 11a;
- residues 9 to 17 of SEQ ID NO:
- 2);
- (t) EOAOVIAHO (sequence 41 of FIG. 11a;
- residues 10 to 18 of SEQ ID NO:
- 2);
- and
- (u) OAOVIAHOF (sequence 42 of FIG. 11a;
- residues 11 to 19 of SEQ ID NO:
- 2).
Dependencies are inferred from the claim text.